Global Cell Therapy Market

Anti-Viral Drug Therapy Market Definition

The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. The anti-viral drug therapy industry includes establishments that manufacture anti-viral drugs, which are used to treat diseases or illnesses caused by viral infections. Examples of antiviral drugs include idoxuridine, famiciclovir, cidofovir, amantadine, zanamivir, tenofovir, adefovir and ribavirin. Viruses are infective agents comprising of a core of nucleic acids, either RNA or DNA, and are surrounded by a layer of protein. These are not living organisms, and can reproduce only inside a living cell. Anti-viral drugs decrease the ability of viruses to reproduce. These drugs enter the cells infected with virus, and interfere with the ability of the virus to bind to the cell, and stimulate the immune system of the host.

Injectable drug delivery devices are used for various routes of drug administration such as intravenous, subcutaneous, intradermal, intra-peritoneal, and intra-muscular. The main types of injectable drug delivery devices are conventional injectable, pre-filled syringes, auto-injectors, and pen-injectors. The prefilled syringes are the packaging with the fixed needle that contains single-dose vaccines or other medications. The injectable drug delivery devices offer applications such as autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, and others that are used by various end-users such as hospitals and clinics, home healthcare settings, pharmaceutical and biotechnological companies, research laboratories, and others. The injectable drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides injectable drug delivery devices market statistics, including injectable drug delivery devices industry global market size, regional shares, competitors with a injectable drug delivery devices market share, detailed injectable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the injectable drug delivery devices industry. This injectable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global injectable drug delivery devices market size will grow from $39.93 billion in 2022 to $43.54 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global injectable drug delivery devices market size is expected to grow from $58.1 billion in 2027 at a CAGR of 7.5%. The increasing preference for self-injection devices is driving the injectable drug delivery devices market. Self-injection devices are medical devices that can be used by the patient in-home setting for self-administration of the medication. Self-injection devices include needle-free, auto, pen, and wearable injectors. These self-injectables were developed to provide the most adaptable device which has a high precision of drug delivery and is easy to use. In addition, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. BD Physioject is a disposable auto-injector, manufactured by Becton, Dickinson, and Company, which is clinically proven, reliable, and cost-effective specifically designed for self-injection of drugs by patients suffering from chronic diseases, including rheumatoid arthritis, multiple sclerosis, asthma, and osteoporosis. The other companies currently involved in the self-injections market include Abbvie, Inc., 3M, Baxter, Gerresheimer AG, Pfizer Inc., and more. The advantages of self-injectable injections and increasing awareness of self-administration have increased the demand for self-injectable devices and will drive the injectable drug delivery devices market during the forecast period. The emergence of alternative drug delivery devices to injectable drug delivery devices is negatively affecting the market. Injectable (parenteral) drug delivery is one of the widely used conventional drug delivery systems. There are many alternative (painless) drug delivery systems such as nasal, transdermal, transmucosal, vaginal, anal, and others that are evolving. The selection of a drug delivery system depends on the drug release, absorption, distribution, metabolism, and elimination profile of the therapeutic agent to achieve the highest level of safety and efficacy from the drug. Alternative drug delivery systems hold key importance in improving bioavailability, reducing toxicity, and safety elimination of drug which is administered to treat a particular disease. Growing disease-related complications, regular developments in drugs, and combinations of therapeutic agents are used to treat disease driving the need for alternative drug delivery systems. There are some recent ongoing developments in the field of alternative drug delivery systems mainly in a nanoparticles-based delivery system, intracellular delivery system, neural delivery system, and many more. Thus, the emergence of alternative drug delivery methods limits the growth of the injectable drug delivery devices market. The companies in injectable drug delivery devices are increasingly focusing on the manufacturing of auto-injectors. The auto-injectors are fully automated, highly customized, and reusable injectors that can be used by a patient to perform hundreds of injections. Patients can control the speed of dose delivery to help minimize pain or discomfort during injection. These devices can adjust the speed and depth of the automatic injection. For instance, LISA, a reusable auto-injector manufactured by Unilife corporation comes with an array of highly customizable features including Bluetooth LE connectivity, Wi-Fi or 3G connectivity, and pre-injection drug warming for target therapies. The injectable drug delivery technology market is expected to show significant growth in the coming years, due to various technological advancements and new product launches to improve the convenience and ease of administration of parenteral therapeutics. Major players in the injectable drug delivery devices market are Becton, Dickinson and Company, Gerresheimer AG, Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Schott AG, Baxter International, Owen Mumford, Mylan N.V., and Sanofi. North America was the largest region in the injectable drug delivery devices market in 2022. Western Europe was the second-largest region in the global injectable drug delivery devices market. The regions in the global injectable drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries included in the injectable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The injectable drug delivery devices market consists of sales of conventional syringes, needle-free injectors, auto-injectors, and pen injectors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global injectable drug delivery devices market is segmented - 1) By Type: Conventional Injectable, Pre-filled Syringes, Auto-injectors, Pen-injectors 2) By Application: Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Pain Management, Respiratory Therapy, Other Applications 3) By End User: Hospitals And Clinics, Home Healthcare Settings, Pharmaceutical And Biotechnological Companies, Research Laboratories, Other End Users

Convalescent plasma is plasma that has been collected from people who have recovered or are convalescing and contains antibodies against the infection-causing microorganism.It is used for the treatment of patients infected by the respective pathogen. The main antibody types of convalescent plasma therapy are IgM, IgG, and IgA. Immunoglobulin A (IgA) is an antibody that is essential for mucous membrane immunological activity. The different applications include prophylaxis, and treatment and are used in various sectors such as hospitals and clinics, laboratories, and research institutes. The convalescent plasma therapy market research report is one of a series of new reports from The Business Research Company that provides convalescent plasma therapy market statistics, including convalescent plasma therapy industry global market size, regional shares, competitors with a convalescent plasma therapy market share, detailed convalescent plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. This convalescent plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global convalescent plasma therapy market size will grow from $0.04 billion in 2022 to $0.05 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global convalescent plasma therapy market size is expected to grow from $0.07 billion in 2027 at a CAGR of 12.0%. Higher efficacy and safety evaluated during the trials conducted for CPT in COVID-19 patients can drive the market growth during the forecast period. Convalescent plasma transfusion has been of interest in the historical period for the treatment of other infectious disease outbreaks such as SARS-1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1. In June 2020, results of a study conducted by the Houston Methodist hospital, which aimed at evaluating safety and efficacy of COVID-19 convalescent plasma therapy, stated that the convalescent plasma therapy is safe with no adverse events reported and is efficient with 76% recovery rate. In May 2020, a study published in the Journal of Medical Virology stated that with convalescent plasma therapy, the mortality rate may be reduced in critically ill patients, beneficial effects on clinical symptoms will be observed, and an increase in neutralizing antibody titers and disappearance of SARS-CoV-2 RNA will be observed. The safety and efficacy of the convalescent plasma therapy in COVID-19 patients will boost market growth. The availability of scant evidence regarding the safety and efficacy of convalescent plasma therapy led to strict guidelines by government authorities. Different government authorities like the US FDA, CDSCO of India, and others have approved COVID-19 convalescent plasma for investigational use only and not for prescribed indication. In May 2020, FDA released guidelines for COVID-19 convalescent plasma therapy, which stated that the administration of COVID-19 convalescent plasma must be under the investigational new drug application (IND) for clinical trials, expanded access, and single-patient emergency only. Even for a single patient emergency, an eIND must be filed with FDA for the use of convalescent plasma therapy, provided, the health care provider must determine that the probable risk from the investigational drug is not greater than the probable risk from the disease or condition. COVID-19 convalescent plasma should be obtained from an FDA-registered blood establishment that follows the donor eligibility criteria and donor qualifications. The manufacturing process and shelf life should be the same as that of other similar plasma products. These strict guidelines framed by authorities are expected to limit the market growth. The development of antibody-based immunotherapy as a potential therapeutic intervention for COVID-19 shows opportunities for the convalescent plasma therapy market. Convalescent plasma therapy utilizes the antibodies produced against coronavirus by the donor to improve the immunity of the recipient. Companies are initiating trials, collaborating and investing for antibody-based COVID-19 therapy. In April 2020, GSK entered into a collaboration with Vir Biotechnology and invested $250 million in Vir to support the development of anti-viral antibody-based solutions against novel coronavirus. In April 2020, Biomedical Advanced Research Development Authority (BARDA) partnered with Emergent BioSolutions to fund $14.5 million to support the development of human plasma-derived therapy which is COVID-Human Immune Globulin (COVID-HIG) for treating COVID-19 in severe hospitalized and high-risk patients. In April 2020, global plasma companies like CSL Behring, Takeda Pharmaceutical Company Limited, Biotest, BPL, LFB, and Octapharma collaborated to develop plasma-derived COVID-19 Hyperimmune Therapy. As convalescent plasma therapy utilizes antibodies, the focus over antibody-based COVID-19 therapy is expected to boost the market growth. In March 2020, Grifols, a Spain-based multinational pharmaceutical and chemical manufacturer that develops, produces, and markets innovative solutions under divisions - Bioscience, Diagnostic, Hospital and Bio Supplies, announced its collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies. Under this collaboration, Grifols will collect plasma from FDA-approved plasma collection centres to develop a hyperimmune globulin as a treatment option for COVID-19 patients and will support the convalescent plasma therapy approach by providing inactivated plasma for transfusion using viral inactivation technology (methylene blue). FDA is a federal agency and BARDA is an authority of the United States Department of Health and Human Services that protects public health through the transition of medical products like vaccines, biopharmaceuticals, pharmaceuticals, and others from research to FDA approval for public use. Major players in the convalescent plasma therapy market are Bio Farma, Grifols, Hilton Pharma, Biotest, BPL, LFB, Octapharma, CSL Behring, Takeda Pharmaceutical Company Limited and Orthosera Kft. North America was the largest region in the convalescent plasma therapy market in 2022. Western Europe was the second largest region in the global convalescent plasma therapy market. The regions covered in the global convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the convalescent plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global convalescent plasma therapy market is segmented - 1) By Application: Prophylaxis, Treatment 2) By End-Users: Hospitals & Clinics, Laboratories & Research institutes 3) By Antibody type: IgM, IgG, IgA

Flow cytometry is a technique in which cells are added to a fluid medium, which is then passed through a pulsating laser beam. The cell then scatters the beam in different directions towards receptors that capture the light and translate it into data displayed on a monitor. Flow cytometry is used to analyze characteristics of a biological cell, such as cell size, cell count, and cell complexity, using laser optics. The main types of flow cytometry are instruments, reagents and consumables, software, accessories, and services. Flow cytometry services include experimental design, specimen processing, acquisition, and data analysis to support researchers, biotech companies, and pharmaceutical companies in the process of drug development. The various technologies involved are cell-based and bead-based and are used in oncology, drug discovery, disease diagnosis, stem cell therapy, organ transplantation, and hematology. The different end-users include hospitals and clinics, academia and research institutes, pharmaceutical and biotechnology companies, and other end users. The flow cytometry market research report is one of a series of new reports from The Business Research Company that provides flow cytometry market statistics, including flow cytometry industry global market size, regional shares, competitors with a flow cytometry market share, detailed flow cytometry market segments, market trends and opportunities, and any further data you may need to thrive in the flow cytometry industry. This flow cytometry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global flow cytometry market size will grow from $5.72 billion in 2022 to $6.25 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global flow cytometry market size is expected to grow to $9.04 billion in 2027 at a CAGR of 9.7%. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. Flow cytometry uses light scattering to determine the identity of cells. These cells are given certain markers called CDs (clusters of differentiation), based on the type of scattering. For the HIV virus cell, the clusters of differentiation is called CD4, and based on the number of CD4s in a medium, flow cytometry can be used to diagnose HIV. As the global HIV population continues to grow, the demand for diagnosis techniques such as flow cytometry is also increasing. The availability of cheaper and better substitutes for flow cytometry is a major restrain on the flow cytometry market. These substitutes include ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay. While flow cytometry, ELISA and radioimmunoassay are all methods that help in HIV diagnosis by detecting “problem cells” in a group of cells, ELISA and radioimmunoassay are cheaper and easier methods than flow cytometry. In ELISA, colour changes in reagents are used to detect problematic cells. While in radioimmunoassay, cells are given certain radioactive markers which are used to detect problematic cells. Both ELISA and radioimmunoassay can be implemented using cheap, traditional laboratory equipment and reagents with a higher throughput rate. However, flow cytometry involves high setup costs and costs of interpreting data along with a very low throughput. High-throughput flow cytometry is an emerging trend in the flow cytometry market. This is due to high speed of cell parameter processing and capability to analyze several heterogeneous cell groups at once, using this technique. Traditional cytometry methods are very slow, especially when several cells need to be tested within a day. Using high-throughput flow cytometry methods such as fluorescence-activated cell-sorting (FACS), multiple cells can be allotted fluorescent markers which can be used to analyze their parameters in quick time. Examples of companies that offer high-throughput flow cytometry solutions include AstraZeneca and Novartis. The US FDA's code of federal regulations (CFR) includes regulations related to a flow cytometry device called the automated differential cell counter (ADCC). An ADCC is a device used in the study of blood cells, mainly for the detection of faulty blood cells and low blood cell counts. This device comes under the purview of the class 2 special controls guidance document which outlines requirements such as the methods for accurate and precise reporting of results, the statistical linearity conditions of graph-based cytometry results and the types of specimens to be used. Flow cytometry device manufacturers must conform to these guidelines, which address the specific health risks associated with ADCC devices. Hence, this is expected to maintain a vigil on flow cytometry companies involved in manufacturing ADCC. In February 2022, KCAS Bioanalytical and Biomarker Services, a US-based GLP and GCP-compliant development service provider, acquired FlowMetric LLc for an undisclosed amount. The acquisition would help KCAS build strong foundations in the field of analytical testing. FlowMetric is a US-based provider of flow cytometry and cellular assay services. Major players in the flow cytometry market are Beckman Coulter, Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher, Luminex, Miltenyi Biotec, Becton Dickinson and Company, Sysmex, Merck KGAA, Danaher Corporation, Apogee, Stratedigm, General Electric Company, EMD Millipore, Affymetrix, Biomérieux S.A., Cytonome St, Enzo Life Sciences, Enzo Biochem, Sony Biotechnology, Sysmex Partec, Life Technologies, BD, ACEA BIO, and TAKARA BIO  North America was the largest region in the flow cytometry market in 2022. Western Europe was the second largest region in the global flow cytometry market. The regions covered in the global flow cytometry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the flow cytometry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The flow cytometry market includes revenue earned by cytometry systems, panel builders, and instruments. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global flow cytometry market is segmented - 1) By Type: Instruments, Reagents & Consumables, Software, Accessories, Services 2) By Technology: Cell-Based, Bead-Based 3) By End User: Hospitals And Clinics, Academia And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users 4) By Application: Oncology, Drug Discovery, Disease Diagnosis, Stem Cell Therapy, Organ Transplantation, Hematology

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system in order to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centres, and others. The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global drugs for immunotherapy market grew from $208.56 billion in 2022 to $231.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The drugs for immunotherapy market is expected to grow from $349.53 billion in 2027 at a CAGR of 10.9%. The immunotherapy drugs market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. For instance, in February 2022, according to a report shared by the WHO, a Switzerland-based specialised agency of the United Nations responsible for international public health, roughly 10 million deaths, or nearly one in six deaths, will be caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the market's growth. The high cost of immunotherapy drugs is acting as a restraint on the drugs for the immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as they are made specifically for each patient, and investment costs in the research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting their market growth. Manufacturers of immunotherapy drugs are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilise Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy. Manufacturers of immunotherapy drugs are governed by various regulatory bodies, such as the Food and Drug Administration in the USA. The Food and Drug Administration (FDA) regulates drugs and biologics under the authority granted to it by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments. Under this authority, FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics, depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins, and some nucleic acids. In August 2020, Bristol Myers Squibb, a US-based pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders, acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million. Through this acquisition, Bristol Myers Squibb will be granted Dragonfly’s extended half-life cytokine DF6002, a monovalent IL-12 immunoglobulin Fc. Dragonfly Therapeutics, Inc. is a US-based discovery-stage company developing drugs to stimulate immune responses against cancer. Major players in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC., Johnson & Johnson, and UbiVac. North America was the largest region in the immunotherapy market in 2022. The Middle East is expected to be the fastest growing region in the global drug for immunotherapy market during the forecast period. The regions covered in the global drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA. The drugs for immunotherapy market consists of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global drugs for immunotherapy market is segmented - 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users

Gene therapy is used for correcting defective genes that are responsible for disease development. Nucleic acid-based therapeutics are used to treat genetic disorders and diseases for which there exists no permanent cure, such as anaemia, sickle cell, cystic fibrosis, and thalassemia. The main technologies in nucleic acid-based gene therapy are anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogues, ribozymes, aptamers, and others. The nucleoside analogues are a significant class of antiviral agents that are generally utilised in the therapy of human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV). The various applications include oncology, muscular dystrophy, muscular disorders, and rare diseases that are used by end-users such as hospitals and clinics and academic and research institutes. The nucleic acid-based gene therapy market research report is one of a series of new reports from The Business Research Company that provides nucleic acid-based gene therapy market statistics, including nucleic acid-based gene therapy industry global market size, regional shares, competitors with a nucleic acid-based gene therapy market share, detailed nucleic acid-based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid-based gene therapy industry. This nucleic acid-based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nucleic acid based gene therapy market grew from $0.68 billion in 2022 to $0.75 billion in 2023 at a compound annual growth rate (CAGR) of 9.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nucleic acid based gene therapy market is expected to grow from $1.06 billion in 2027 at a CAGR of 9.2%. Rising financial support by the government and the companies is projected to drive the demand for nucleic acid-based gene therapy. Nucleic acid therapeutics are analogs of naturally occurring acids or proteins responsible for genetic expression. The traditional therapies do not have any cure for the treatment of diseases such as cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. Genetic profiling and molecular target identification form the backbone of these classes of drugs. Nucleic acid medication has greater potential for the treatment of these diseases, as they target the genetic basis of diseases and have a permanent cure. Rising financial support by the government and the companies dealing in the market for gene therapy is expected to contribute to increasing the demand for nucleic acid-based gene therapies. For instance, in August 2022, National Institute of Health (NIH) announced investment of $34 million annually for upcoming 5 years to develop HIV treatment research. The government support for gene therapies will contribute to the growth of the market. Stringent regulations imposed on gene therapies raise the price of gene therapies, which in turn hinders the demand for nucleic acid-based gene therapies. The excessive regulatory oversights create an expensive and elongated route for approval increasing the expenses. According to Foundation for Economic Education (FEE), unlike other drugs approved or regulated by the Food and Drug Administration (FDA), gene therapies are not only subject to the regulatory structure of the FDA, but also the Recombinant DNA Advisory Committee and Office of Biotechnology Activities. Also, as estimated by FEE, an approved gene therapy drug costs nearly $5.0 billion, which is five times higher than that of the average cost of FDA approval. The high cost of gene therapeutics drugs places them beyond the financial reach of the populace. This scenario is anticipated to restrain the market growth of the nucleic acid-based gene therapy market. The companies in the nucleic acid based gene therapy market are focusing on strategic partnerships and collaborations to help boost production. Major players are entering into partnership to expand their market and leverage each other’s resources. For example, in January 2022, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation, and Beam Therapeutics Inc., an American biotechnology company developing precision genetic medicines through base editing, announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. Similarly, in August 2022, Merck, an American multinational pharmaceutical company, and Orna Therapeutics, a US based biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Major players in the nucleic acid-based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene, Caperna, Phylogica, Protagonist Therapeutics, Benitec Biopharma, EGEN, BioMedica, Transgene, and Copernicus Therapeutics. North America was the largest region in the nucleic acid-based gene therapy market in 2022. Western Europe was the second largest region in the global nucleic acid-based gene therapy market report.The regions covered in the global nucleic acid-based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the nucleic acid-based gene therapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The nucleic acid based gene therapy market consists of sales of nucleic acid based gene therapy technologies such as anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogs, ribozymes, aptamers, and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part. The global nucleic acid based gene therapy market is segmented - 1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies 2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases 3) By End User: Hospitals And Clinics, Academic And Research Institutes

Plasma therapy refers to a treatment that substitutes missing or inadequate proteins to help people live healthier and more fruitful lives. It introduces antibodies into individuals receiving therapy using blood donated by recovered patients. The main types of plasma therapy are pure PRP, leukocyte-rich PRP, pure platelet-rich fibrin (PRF), and leukocyte-rich fibrin (L-PRF). Pure Platelet-Rich Plasma (P-PRP) or leucocyte-poor PRP goods are activated preparations that lack leucocytes and have a low-density fibrin system. The different applications include orthopedics, arthritis, chronic tendinitis, bone repair and regeneration, dermatology, androgenic alopecia, plastic surgery, dental, cardiac muscle injury, and others and are implemented in various sectors such as hospitals and clinics, laboratories, and research institutes. The plasma therapy market research report is one of a series of new reports from The Business Research Company that provides plasma therapy market statistics, including plasma therapy industry global market size, regional shares, competitors with a plasma therapy market share, detailed plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the plasma therapy industry. This plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global plasma therapy market grew from $0.4 billion in 2022 to $0.44 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The plasma therapy market is expected to grow from $0.69 billion in 2027 at a CAGR of 11.7%. The rising prevalence of osteoarthritis is expected to drive the plasma therapy market during the forecast period. Platelet-rich plasma (PRP), a type of plasma therapy, is considered a safe and efficient treatment for osteoarthritis. Platelet-rich plasma (PRP) is a concentrated autologous blood growth factor that is injected into the joint to provide symptomatic relief by decreasing inflammation and slowing the progression of osteoarthritis. For instance, in July 2020, according to the Centers for Disease Control and Prevention (CDC), around 32.5 million people in the USA will be suffering from osteoarthritis. Some of the most commonly used treatments for osteoarthritis are autologous chondrocyte implantation and scaffold implants. Therefore, an increase in the prevalence of osteoarthritis is expected to drive the plasma therapy market. The high cost of plasma therapy is expected to hinder the market. The major reason contributing to the high cost is due to extraction and storage. Plasmapheresis is the process of separating plasma and blood cells from blood.The cost of plasmapheresis is approximately $5,000 to $10,000 in the United States. Average platelet-rich plasma orthopaedic treatment costs range from $350 to $1,050 for a single sitting, and it may require 2 to 3 settings for the treatment to be effective. The high cost of plasma therapy hinders many patients from accessing the treatment, thereby impacting the market negatively. Convalescent plasma therapy, to treat patients suffering from COVID-19, is a leading trend in the plasma therapy market. Convalescent plasma is the plasma extracted from individuals who have been cured of a particular viral infection, as they have antibodies that protect and make them immune to that particular organism. The convalescent plasma is transfused to the patient who is suffering from the viral infection to neutralise the infection and induce an active immune response to cure the infection. Convalescent plasma therapy is found to be a safe treatment to cure patients infected with the coronavirus. Moreover, this therapy was used to treat other viral infections such as Ebola, Dengue, and SARS-1 but did not give the desired results. In March 2020, Takeda Pharmaceutical Company Limited has initiated a plasma therapy, Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), which is termed TAK-888 for treating COVID-19. The TAK-888 utilises the plasma collected from convalescent donors who have been cured of COVID-19 and is administered to the patient suffering from COVID-19. Major players in the plasma therapy market are Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Arthrex, Inc., Biotest AG, China Biologic Products Holdings, Inc., DePuy Synthes Companies, CSL Limited, Grifols, S.A., Octapharma, and Terumo BCT Inc. North America is the largest region in the Remdesivir market in 2022. The Middle East is expected to be the fastest growing region in the global plasma therapy market during the forecast period. The regions covered in the global plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The plasma therapy market includes revenues earned by entities by replacing missing or deficient proteins and developing better means of managing the disease. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global plasma therapy market is segmented - 1) By Type: Pure PRP, Leukocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF) 2) By Application: Orthopaedics, Arthritis, Chronic Tendinitis, Bone Repair & Regeneration, Dermatology, Androgenic Alopecia, Plastic Surgery, Dental, Cardiac Muscle Injury, Other Applications 3) By End-Users: Hospitals & Clinics, Laboratories: Research Institutes

Tumor ablation therapy devices are minimally invasive devices used in the treatment of tumors, commonly of kidney, liver and lung. The main technologies in the tumor ablation therapy devices are radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others. Irreversible electroporation (IRE) in tumor ablation therapy is a new tissue ablation method in which micro to millisecond electrical pulses are supplied to undesirable tissue to produce cell necrosis by irreversible cell membrane permeabilization. The treatments included are surgical, laparoscopic, and percutaneous that are used in various applications such as kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and others. The various end-users of tumor ablation therapy devices are hospitals, oncology clinics, and others. The tumor ablation therapy devices market research report is one of a series of new reports from The Business Research Company that provides tumor ablation therapy devices market statistics, including tumor ablation therapy devices industry global market size, regional shares, competitors with a tumor ablation therapy devices market share, detailed tumor ablation therapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor ablation therapy devices industry. This tumor ablation therapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global tumor ablation therapy devices market grew from $0.56 billion in 2022 to $0.64 billion in 2023 at a compound annual growth rate (CAGR) of 15.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The tumor ablation therapy devices market is expected to grow from $1.1 billion in 2027 at a CAGR of 14.4%. The increasing prevalence of cancer is a key factor driving the growth of the tumor ablation therapy devices market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. Tumor ablation is a minimally invasive procedure widely used in the treatment of lung, liver, kidney, and bone tumors. For instance, in 2020, according to the American Institute of cancer research, there were an estimated 18.1 million cancer cases around the world. It was estimated that 9.3 million cases were in men and 8.8 million in women. Among them, lung and breast cancers are the most common cancers in the world, and about 12.5% and 12.2% of the new cases are diagnosed in 2020. The procedure is an effective method for patients who have failed chemotherapy or radiotherapy, thereby supporting the growth of the tumor ablation therapy devices market. Product recalls of tumor ablation devices due to technical issues are expected to hinder the growth of the tumor ablation therapy devices market. The companies are retrieving their products from the market due to safety concerns. For instance, COVIDien Emprint Long Percutaneous Antenna with Thermosphere Technology, a tumor ablation device from Medtronic had recalled its devices due to the disengagement of ceramic trocar tip of the Emprint ablation from the needle shaft post-ablation. Similarly, in June 2018, Accurian RF Ablation by Medtronic Sofamor Danek USA Inc. was recalled due to the difficulty in insertion. The product recalls caused a financial burden on the companies hindering the tumor ablation therapy devices market. Major companies operating in the tumor ablation therapy devices are focusing on technology advancements for shorter procedures, increased safety, lower exposure to radiation, faster learning curves, and improved outcomes J&J medicals have released a microwave ablation system called NEUWAVE, which is the first minimally invasive device to put electrodes into cancer cells and thereby increase the temperature around them for burning the cancer cells. In June 2020, Boston Scientific has launched a technology called DirectSense technology, a tool used for monitoring the effect of radiofrequency (RF) now for cardiac procedures, which may be further employed for tumors. In August 2022, Imagin Medical, a Canada-based urologic oncology company acquired enCAGE Coil™ Precision Ablation System for Prostate Cancer from TROD Medical NV for $2.5m. The acquisition would strengthen Imagin’s position as a urologic oncology company and expand its portfolio in the field of prostate cancer. TROD Medical NV is a Belgium-based medical device company. Major players in the tumor ablation therapy devices market are Galil Medical Inc., Misonix Inc., HealthTronics, Angiodynamics, Boston Scientific Corporation, Medtronic PLC., EDAP TMS S.A, Neuwave Medical Inc., BVM Medical Limited, and Erbe Elektromedizin GmbH. North America was the largest region in the tumor ablation therapy devices market in 2022. Asia-Pacific was the second largest region in the global tumor ablation therapy devices market. The regions covered in the global tumor ablation therapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the tumor ablation therapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The tumor ablation therapy devices market consists of sales of radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others that are used for tumor ablation therapies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global tumor ablation therapy devices market is segmented - 1) By Technology: Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation, Other Technologies 2) By Treatment: Surgical, Laparoscopic, Percutaneous 3) By End User: Hospitals, Oncology Clinics, Other End Users 4) By Application: Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Other Applications